CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Health officials repeated safety concerns about an experimental group of HIV drugs Friday, days before government advisers will recommend whether the first drug from the class merits approval.
Pfizer seeks Food and Drug Administration approval for maraviroc, potentially the first in a novel group of drugs to fight HIV, the virus that causes AIDS. Pfizer proposes marketing maraviroc as Celsentri.
Pfizer believes there is a clear unmet need for new drugs to fight HIV in patients for whom other, older drugs no longer work. Celsentri is unlike any other HIV medicines now on the market in that it targets the cells of patients and not the virus itself.
The FDA has scheduled a Tuesday meeting of outside experts to discuss Pfizer's application for approval. The FDA has asked the experts whether Celsentri, if approved, would require special labeling or if further study of the drug's safety is needed before it can be sold. FDA also asked whether the drug should be studied further in women and blacks.
The FDA and Pfizer both said that studies showed adding Celsentri to a traditional HIV treatment regimen was more effective in dropping the virus below detectable levels in patients.
But the FDA continues to be concerned about potential safety issues with the entire class of drugs, called CCR5 receptor antagonists. Those issues include the possibility the drugs could increase the likelihood of infection, lymphoma, or liver damage in HIV patients. They've also been linked to heart rhythm changes in laboratory animals.
Most worrisome is that the drugs could accelerate a shift from one variant of HIV to a second, which is most often seen in the sickest AIDS patients. Patients on Celsentri likely would have to be tested regularly to monitor whether the drug is driving such a shift.
Still, FDA reviewers noted no increase in lymphomas or infections among patients given Celsentri but said there was a modest increase in liver problems.
Pfizer, in its own analyses of studies of the drug, said the studies showed no significant effect on the heart, and no increased incidence of liver problems, cancer, or infection compared with treatment with other HIV drugs.
Previously, those sorts of safety concerns set back GlaxoSmithKline and Schering-Plough in their development of similar CCR5 receptor antagonists.
The drugs block a secondary but crucial doorway typically used by the human immunodeficiency virus to enter white blood cells. A body's white blood cells play an important role in the immune system.
Researchers have known for more than a decade that people who lack a working version of that doorway, called a receptor, are at best highly resistant to infection by HIV and at worst slow to develop AIDS once infected.
Since 1987 the FDA has approved 29 drugs, including combination medicines, in four different classes to fight HIV. CCR5 receptor antagonists would represent a new fifth class. (Andrew Bridges, AP)
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Here Are Our 2024 Election Predictions. Will They Come True?
November 07 2023 1:46 PM
17 Celebs Who Are Out & Proud of Their Trans & Nonbinary Kids
November 30 2023 10:41 AM
Here Are the 15 Most LGBTQ-Friendly Cities in the U.S.
November 01 2023 5:09 PM
Which State Is the Queerest? These Are the States With the Most LGBTQ+ People
December 11 2023 10:00 AM
These 27 Senate Hearing Room Gay Sex Jokes Are Truly Exquisite
December 17 2023 3:33 PM
10 Cheeky and Homoerotic Photos From Bob Mizer's Nude Films
November 18 2023 10:05 PM
30 Steamy Photos of Folsom Street Fair 2023 Debauchery
October 15 2023 11:06 PM
42 Flaming Hot Photos From 2024's Australian Firefighters Calendar
November 10 2023 6:08 PM
These Are the 5 States With the Smallest Percentage of LGBTQ+ People
December 13 2023 9:15 AM
60 Burly Pics from Bearrison Street Fair 2022
October 08 2023 8:30 PM
Watch Now: Advocate Channel
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Latest Stories
We kiki with Jake Shears about Cabaret, Tammy Faye, Elton, and more
March 25 2024 9:52 AM
Prince William's aversion to spectacle created one — and might spawn a King Harry
March 22 2024 6:24 PM
Outrage after Oklahoma prosecutor declines charges in Nex Benedict bullying death
March 22 2024 5:21 PM
George Santos leaves Republican Party, will run for House seat as independent
March 22 2024 4:07 PM
Catherine, Princess of Wales, announces she has cancer
March 22 2024 2:57 PM
Pride
Yahoo FeedProhibition Wellness & revolutionizing self-care for all
March 22 2024 1:19 PM
Tennessee bill would permit anti-LGBTQ+ foster and adoptee parents
March 22 2024 11:54 AM